The synthetic DNA technology developer, which counts Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux, has filed to raise up to $86.3m.
US-based synthetic DNA producer Twist Bioscience has filed for an $86.3m initial public offering that would enable corporate investors Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux to exit.
Twist Bio has created a DNA synthesis platform that facilitates the manufacturing of synthetic DNA which is in effect written on a silicon chip. In addition to artificial DNA, it can form tools for sample preparation or antibodies that can be used in drug discovery.
The IPO proceeds will partially support…
